News & Stories

See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.

CMT Research Foundation Elects Board Member Cleary Simpson to Chief Executive Officer

Jan 10, 2022 | News

By Patrick Livney, Board Chair and Co Founder As we move from being a startup to the leading foundation seeking to cure CMT, we can look back with great pride on our progress to date: We have raised almost $10 million in three years, funded 12 projects (with two in...

Michele and Kent Stahl and Family Give $1,000,000 to the CMT Research Foundation to Develop Treatments for CMT1A

Jan 4, 2022 | Press Releases

Atlanta (January 4, 2021) Michele and Kent Stahl and their family today announce a $1 million donation to support the CMT Research Foundation’s $10 million ENDGAME: the Campaign to End CMT1A. Since the soft launch of ENDGAME in September, families and friends with...

Why Michele and Kent Stahl and their family made a $1,000,000 gift to CMT Research Foundation to develop treatments for CMT1A

Jan 4, 2022 | Life with CMT, News, Press Releases

Michele and Kent’s son, Austin, was diagnosed with CMT1A when he was 16 years old. Having difficulty with his balance and walking, it took years for him and his family to understand the cause. His mother Michele recounts, “we spent seven years searching for an answer....

2021 Year in Review

Dec 31, 2021 | News

2021 has been a banner year for progress in CMT drug development, much of which has been possible because of your partnership with the CMT Research Foundation – thank you! Despite the challenges presented by a global pandemic, we can be proud of all that we were able...

Teams at Cyprus Institute of Neurology & Genetics and Nationwide Children’s Hospital Complete CMT Research Foundation-Funded Project, Resulting Therapeutic Now Moving into Pharmaceutical Development

Dec 16, 2021 | CMT Research Updates, CMTRF Funded Research, Drug Development

Update, May 17, 2022: This work is now published in The Journal of Clinical Investigation. The CMT Research Foundation is pleased to announce that Dr. Kleopas Kleopa, a renowned neuromuscular disease expert, CMT scientist, and clinician, and his team from the Cyprus...

CMT Research Foundation Funds Cutting Edge Research to Deliver Therapeutics to the Peripheral Nervous System

Nov 19, 2021 | CMT Research Updates, CMTRF Funded Research, Drug Development, Research News

The CMT Research Foundation has awarded nearly $100,000 to support a 13-month project to test a new therapeutic delivery system that may be capable of crossing the blood-nerve barrier and releasing therapeutic payloads to the Schwann cells and axons of the peripheral...

Changing One Family’s Legacy

Sep 17, 2021 | Life with CMT

As with many families, I am but one leaf in a family tree colored by CMT1A across its many limbs and branches. I have watched successive generations struggle with the disease’s progressively debilitating physical symptoms and persistent emotional toll: grandparents,...

The CMT Research Foundation Kicks Off September CMT Action Month

Sep 10, 2021 | News

Each September we join with other organizations to build awareness for Charcot-Marie-Tooth Disease. As you know, CMT is little-known and poorly understood outside of the patient community and we celebrate each and every effort to educate the medical community, the...

Researchers at Cyprus Institute of Neurology & Genetics Complete Third Milestone of CMT1A Gene Therapy Project

Aug 30, 2021 | CMT Research Updates, CMTRF Funded Research, News

The CMT Research Foundation is pleased to announce that Dr. Kleopas A. Kleopa and his team at the Cyprus Institute of Neurology & Genetics, Nicosia, have completed the third milestone of their 24-month CMT1A gene therapy project. CMT1A is caused by duplication of...

DTx Pharma, Inc. Completes CMT Research Foundation-Funded Project

Aug 27, 2021 | CMT Research Updates, CMTRF Funded Research, Drug Development

The CMT Research Foundation is pleased to announce that DTx Pharma, Inc. (DTx) has successfully completed their CMT Research Foundation-funded RNA-based therapy project. With funding from the CMT Research Foundation, DTx designed and tested a library of novel...